March 9, 2004

News Release: DiagnoCure launches automated version of its ImmunoCyt(TM)/uCyt+(TM) bladder cancer test

DiagnoCure Inc. (TSX: CUR), a leading developer and provider of molecular diagnostic tests for the early detection of cancers, today announced the launch of Odyssee(TM), the first automated version of its non-invasive bladder cancer test ImmunoCyt(TM)/uCyt+(TM). This market introduction is taking place at the Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) currently being held from March 6- 12, 2004, in Vancouver, Canada.

As an automated workstation for microscopy slide analysis in the monitoring of bladder cancer, Odyssee(TM) provides a highly cost-effective solution to the growing practice requirements of pathology laboratories. Odyssee(TM) is powered by uCyt+(TM) Suite, a dedicated image analysis software and patient management system developed by Samba Technologies SAS, DiagnoCure's wholly owned subsidiary. The system screens, detects, reports, and archives data and images from ImmunoCyt(TM)/uCyt+(TM) fluorescent slides. It thus allows laboratories with high-volume urine cytologies to maximize the efficiency of their operations.

Based on ten (10) studies conducted on over 2,000 patients, ImmunoCyt(TM)/uCyt+(TM) has been increasingly recognized as the optimal adjunct to urine cytology in the management of recurrent bladder cancer. Using fluorescent label probes, ImmunoCyt(TM)/uCyt+(TM) provides information beyond morphology, thus improving the detection of low and high-grade tumors as well as carcinoma in situ (CIS). The launch of an automated ImmunoCyt(TM)/uCyt+(TM) test represents a significant milestone in DiagnoCure's planned commercialization strategy.

About DiagnoCure

DiagnoCure specializes in the development, production and commercialization of diagnostic tests for the early detection of cancers. DiagnoCure's first product, ImmunoCyt(TM)/uCyt+(TM), is an important tool for the diagnosis and monitoring of bladder cancer. In 2003, the company completed the development of uPM3(TM), a non-invasive test for the early detection of prostate cancer. The company launched this test in the ASR format through Bostwick Laboratories'network. In November 2003, DiagnoCure granted an exclusive worldwide license for the use of the PCA3 technology in prostate cancer diagnosis to Gen-Probe (NASDAQ: GPRO). DiagnoCure is actively pursuing the development of a prototype test for detection of lung cancer and has initiated identification and validation of markers for kidney cancer detection. The company is headquartered in Quebec City, Canada. Additional information can be found at www.diagnocure.com .

Forward-looking statements Certain statements in this release are forward-looking. These statements are based on DiagnoCure's current expectations and involve many risks and uncertainties. DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
SOURCE DIAGNOCURE INC.

Pierre Desy, President and CEO, DiagnoCure Inc., (418) 527-6100, This email address is being protected from spambots. You need JavaScript enabled to view it. (CUR.)

WEBSITE EMAIL